Drug Type Antibody drug conjugate (ADC) |
Synonyms SCR A008, SCR-A008, SCRA008 + [2] |
Target |
Action antagonists, inhibitors |
Mechanism CDH17 antagonists(Cadherin-17 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 07 Nov 2025 | |
| Solid tumor | Phase 1 | China | 31 Oct 2025 | |
| Locally Advanced Malignant Solid Neoplasm | IND Approval | China | 05 Sep 2025 | |
| Metastatic Solid Tumor | IND Approval | China | 05 Sep 2025 | |
| CDH17-positive Solid Tumor | Preclinical | China | 29 Apr 2025 | |
| Gastrointestinal Neoplasms | Preclinical | China | 29 Apr 2025 |






